Clinical outcomes of tumor-agnostic targeting of BRAF, tumor mutation burden-high, and RET.

ESMO Open · 2025 · PMC12167085 · PMID 40460677

Europe PMC DOI

hedged sentence

0.0760

closest p · 1.5× alpha

0.0760

boldest claim

The sentences

a favorable trendP = 0.076so close (0.05 < p ≤ 0.1)

In the BRAF V600E cohort, the mPFS showed a favorable trend for the GMT ( n = 62, median 9.2 months, 95% CI 5.8-17.0 months) versus the non-GMT group ( n = 20, median 4.2 months, 95% CI 2.3 months-NE, P = 0.076, HR 0.59, 95% CI 0.33-1.06).

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.